GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has cleared its SenoBright contrast-enhanced spectral mammography (CESM) application for breast cancer diagnosis.
SenoBright technology works as an upgrade to GE's Senographe DS and Senographe Essential digital mammography equipment, the firm said. The system is designed to produce contrast-enhanced images of the breast using an x-ray contrast agent and a dual-energy acquisition technique.
Launched in 2010, SenoBright is already in use at 17 mammography centers in France, Spain, Italy, Belgium, Germany, Austria, and Japan, according to GE.
